BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02608229 |
Recruitment Status :
Terminated
(Adverse events)
First Posted : November 18, 2015
Results First Posted : May 1, 2020
Last Update Posted : June 4, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreatic Cancer Cancer of Pancreas Cancer of the Pancreas Pancreas Cancer | Drug: BVD-523 Drug: Nab-paclitaxel Drug: Gemcitabine Procedure: Tumor biopsy | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 18 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer |
Actual Study Start Date : | June 6, 2016 |
Actual Primary Completion Date : | March 27, 2019 |
Actual Study Completion Date : | May 21, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Dose De-escalation: BVD-523/Nab-paclitaxel/Gemcitabine
|
Drug: BVD-523 Drug: Nab-paclitaxel Other Names:
Drug: Gemcitabine Other Names:
Procedure: Tumor biopsy |
Experimental: Dose Expansion: BVD-523/Nab-paclitaxel/Gemcitabine
|
Drug: BVD-523 Drug: Nab-paclitaxel Other Names:
Drug: Gemcitabine Other Names:
Procedure: Tumor biopsy |
- Maximum Tolerated Dose (MTD) of BVD-523 [ Time Frame: Completion of cycle 1 for all dose de-escalation patients (1.8 years), the first cycle is 28 days for each individual patient ]-The maximum tolerated dose (MTD) is defined as the Dose Level 1 if 0 or 1 dose-limiting toxicities (DLTs) are seen in patients at that dose level or Dose Level -1 if 2+ DLTs are seen in Dose Level 1 but only 0 or 1 DLTs are seen in patients at Dose Level -1.
- Safety and Toxicity Profile of Treatment Regimen as Measured by Grade and Frequency of Adverse Events [ Time Frame: 30 days after completion of treatment (median time was 67.5 days) ]-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.
- Response Rate [ Time Frame: Through completion of treatment (median time was 37.5 days) ]
- Response rate is the percentage of participants with best response of complete response or partial response per RECIST 1.1
- Complete response (CR): disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Disappearance of all non-target lesions and normalization of tumor marker level.
- Partial response (PR): at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
- Biochemical Response of Treatment Regimen [ Time Frame: Through completion of treatment (median time was 37.5 days) ]-The biochemical response (BR) is defined as more than 50% of decrease from baseline CA 19-9
- Time to Tumor Progression (TTP) [ Time Frame: Up to 2 years ]
- Time to tumor progression is defined as the days from start of treatment until progressive disease.
- Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
- Progression-free Survival (PFS) [ Time Frame: Up to 2 years ]
- Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
- PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Patients alive without progression or lost to follow-up are censored.
- Overall Survival (OS) [ Time Frame: Up to 2 years ]-OS is defined as the days from the date of treatment start and death from any cause. Patients alive or lost to follow-up are censored.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or cytologically confirmed newly diagnosed treatment-naïve metastatic adenocarcinoma of the pancreas with metastatic disease diagnosed no more than 6 weeks prior to enrollment. Patients with advanced pancreatic cancer progressed on 5-FU (or capecitabine) based regimen will be allowed in the expansion cohort.
- Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan or MRI, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam.
- At least 18 years of age.
- Life expectancy > 3 months.
- ECOG performance status ≤ 1
-
Normal bone marrow and organ function as defined below:
- Absolute neutrophil count ≥ 1,500/mcL
- Platelets ≥ 100,000/mcL
- Hemoglobin ≥ 9.0 g/dL
- Total bilirubin ≤ IULN
- AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN, unless there are liver metastases in which case AST and ALT ≤ 5.0 x IULN
- Creatinine ≤ 1.5 x IULN OR GFR of ≥ 50 mL/min
- Cardiac function ≥ ILLN, e.g., LVEF of > 50% as assessed by MUGA or ECHO, QTc < 470 ms
- Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for three months following study discontinuation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
- Current use or anticipated need for alternative, holistic, naturopathic, or botanical formulations used for the purpose of cancer treatment.
- A history of other malignancy with the exception of those treated with curative intent with no evidence of disease for 2 years.
- Currently receiving any other investigational agents.
- Known brain metastases or CNS involvement.
- Significant ascites that require therapeutic paracentesis.
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BVD-523, gemcitabine, nab-paclitaxel, or other agents used in the study.
- Neuropathy ≥ grade 2.
- History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
- History of interstitial lung disease or pneumonitis.
- Concurrent therapy with drugs known to be strong inhibitors of CYP1A2, CYP2D6, and CYP3A4, or strong inducers of CYP3A4 (see Appendix B).
- Gastrointestinal condition which could impair absorption of BVD-523 or inability to ingest BVD-523.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of study entry.
- Known HIV-positivity.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02608229
United States, Missouri | |
Washington University School of Medicine | |
Saint Louis, Missouri, United States, 63110 |
Principal Investigator: | Andrea Wang-Gillam, M.D., Ph.D. | Washington University School of Medicine |
Documents provided by Washington University School of Medicine:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT02608229 |
Other Study ID Numbers: |
201601098 5P50CA196510-02 ( U.S. NIH Grant/Contract ) |
First Posted: | November 18, 2015 Key Record Dates |
Results First Posted: | May 1, 2020 |
Last Update Posted: | June 4, 2020 |
Last Verified: | May 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Gemcitabine Paclitaxel Albumin-Bound Paclitaxel Antineoplastic Agents, Phytogenic Antineoplastic Agents |
Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |